← Eichor
Study identifier: NCT03240328 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function

Condition: HIV/AIDS  ·  Sponsor: Guangzhou 8th People's Hospital

PhasePhase 1
Planned participants40
Who can joinAll sexes, 18 Years to 60 Years
Healthy volunteersNo

About this study

To study the safety and effectiveness of CAR-T Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after cART, which is expected to enhance the res-constitution of HIV-specific immune function to assist the eradication of HIV reservoir.

This description comes directly from the study's public registry record.

Talk to the study team

Li Linghua, Doctor  ·  020-83710825  ·  llheliza@126.com

Cai Weiping, Bachelor  ·  020-83710816  ·  gz8hcwp@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Guangzhou 8th People's HospitalGuangzhou, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03240328